APA

Basu B., Vitfell-Pedersen J., Moreno Garcia V., Puglisi M., Tjokrowidjaja A., Shah K., Malvankar S., Anghan B., de Bono J. S., Kaye S. B., Molife L. R. & Banerji U. (20121108). Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials. : Oncology.

Chicago

Basu B, Vitfell-Pedersen J, Moreno Garcia V, Puglisi M, Tjokrowidjaja A, Shah K, Malvankar S, Anghan B, de Bono J S, Kaye S B, Molife L R and Banerji U. 20121108. Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials. : Oncology.

Harvard

Basu B., Vitfell-Pedersen J., Moreno Garcia V., Puglisi M., Tjokrowidjaja A., Shah K., Malvankar S., Anghan B., de Bono J. S., Kaye S. B., Molife L. R. and Banerji U. (20121108). Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials. : Oncology.

MLA

Basu B, Vitfell-Pedersen J, Moreno Garcia V, Puglisi M, Tjokrowidjaja A, Shah K, Malvankar S, Anghan B, de Bono J S, Kaye S B, Molife L R and Banerji U. Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials. : Oncology. 20121108.